Summary Gene-transfected tumour cells were used to cure mice bearing lung metastases by the parental, nontransduced mammary adenocarcinoma (TSA-pc). Repeated subcutaneous (s.c.) administrations of mitomycin C (MitC)-treated interferon y (IFN-y) transfectants induced a 90% inhibition in the number of lung metastases. Therapeutic effect required an intact T-cell response, as shown by the lack of efficacy in nude mice. Autocrine stimulation by IFN-y induces specific modifications in the phenotype of transfectants that acquire a high metastatic ability and show a high expression of IFN-responsive genes; these two features were exploited to design two experimental protocols to obtain an improvement of the therapeutic effect. The increased metastatic ability of IFN-y transfectants was used to deliver IFN-y selectively to the lungs of mice bearing TSA-pc pulmonary metastases. A significant therapeutic effect was obtained when TSA-pc experimental metastases were treated by repeated intravenous (i.v.) injections of MitC IFN-y transfectants. Since i.v. administrations of IFN-y transfectants did not induce immune memory, the therapeutical effect appeared to depend on the inflammatory-like response activated by local IFN release. To exploit the autocrine stimulation of IFNsensitive genes an IFN-y transfectant clone was subjected to a second transfection with an allogeneic class I MHC gene (H-2Kb or H-2Db). IFN-y plus MHC double transfectants maintained IFN-y release, showed a very high expression of the MHC gene products, stimulated both macrophages and T cells, and were less tumorigenic in immunocompetent mice than the parent IFN-y clone. Therapeutic efficacy of double transfectant IFN-y plus H-2Db cells against TSA-pc was superior to single transfectants, showing that the reaction elicited by genetically engineered cells can be selectively tuned to increase therapeutic efficacy.
The use of gene transduction has considerably expanded the range of tools available for the immunotherapy of tumours. Protection from tumour growth in preimmunised animals has been obtained with tumour cells transduced with genes for various cytokines and surface antigens (Tanaka et al., 1986; Ostrand-Rosenberg et al., 1991; Colombo and Forni, 1994) . However, realistic therapeutic protocols, in which engineered cells are administered only after the challenge with live parent tumour cells, have been explored less frequently.
Malignant tumour cells transduced with foreign genes are a complex biological reagent. In fact, they should be regarded as a novel type of tumour, rather than as a passive immunological vaccine. In particular, some of the cytokines used for this type of studies are active both on the host immune system and on the tumour itself. In particular, interferon (IFN) gene transduction profoundly alters several properties of the transformed cells, including upmodulation of MHC, resistance to natural killer (NK) cells and metastatic ability (Watanabe et al., 1989; Gansbacher et al., 1990; Restifo et al., 1992; Lollini et al., 1993) .
In principle, genes coding for class I major histocompatibility complex (MHC) should modify the interaction of tumour cells with the immune system only, but it has been clearly shown that after transfection of MHC genes a few properties of the neoplastic cells are also modified (De Giovanni et al., 1994) .
These considerations suggest that the biological properties of recipient tumour cells must be adequately characterised, before and after gene transfer, to exploit the possibilities offered by this technology fully. In this work we show how to take advantage for therapeutic purposes of some specific modifications induced by transfection of the IFN-y gene in a mammary carcinoma.
Materials and methods
Cells and DNA transfection TSA-pc is a tumour cell line we derived from a spontaneous mammary adenocarcinoma of the BALB/c strain; TSA-pc cells give rise to moderately differentiated, non-capsulated invasive tumours, which are highly metastatic and poorly immunogenic in syngeneic mice (Lollini et al., 1993) . TSA-pc has been used as the recipient of several cytokine genes , including IFN-y (Lollini et al., 1993) . TSA-IFNy500 and TSA-IFNy"0 were obtained from TSA following gene transfection with the murine IFN-y gene and release 500 and 6000 IU ml-' of IFN-y (Lollini et al., 1993) ; TSA-neo control was transfected with the neomycin resistance gene alone (Lollini et al., 1993) . Clone TSAIFNy 6" was subsequently transfected with allogeneic H-2K' and H-2Db genes (Lollini et al., 1995) (Lollini et al., 1993) . In some experiments, 5"Crlabelled TSA-pc cells were also used to evaluate 4 h release in the presence of effectors obtained as above, but very low values of cytotoxicity were obtained owing to the resistance to lysis of TSA-pc target cells (data not shown). Maximum release was determined by adding 0.1 ml of 10% Triton X-100. Values of spontaneous release were within 10-15%. The release values are expressed as lytic units (LU) calculated as described (Lollini et al., 1993) . One LU is here defined as the number of effector cells needed to kill 20% of the target cells (LU20). a Statistical anal'.sis The non-parametric Wilcoxon's rank-sum test was used to compare numbers of metastases.
Results

Inmnmunogenicitv of TSA-IFN-clones
TSA-pc is a highly malignant tumour, and expression of the IFN-j; gene did not abolish completely the tumorigenicity of clones TSA-IFN;500 and TSA-IFN-.6"". (which release 500 and 6000 IU ml-' IFN-; respectively), thus mitomycin-C-treated (MitC) cells were used for therapeutic administrations. MitC cells retain for several days the ability to release IFN-j;, as shown by reverse transcriptase -polymerase chain reaction and IFN-; bioassay (data not shown).
We have previously shown that the reduced tumorigenic potential of IFN-; clones was mainly caused by the local activity of macrophages. However, tumour infiltrate also contained activated lymphocytes (Lollini et al., 1993) . IFN-, clones induced memory cells directed against the parent tumour TSA-pc; mice immunised with IFN-; clones were protected against a subsequent challenge with TSA-pc (Musiani et al., 1994) . Mice immunised with TSA-IFN; 500 or TSA-IFN-6"00 displayed a stronger cytotoxicity against TSA-pc than mice immunised with TSA-pc or TSA-neo ( Figure 1 ).
T.qrnpt-T.I;A-nr:
TSA-pc Metastasis-free mice (%) Figure 2) , showed that an intact T-cell response is required for the cure of lung metastases.
SCl'lltal'gC'tiI7gr *)f tI'bl1,SIc'c'tan/ts a Therefore, the therapeutic effect of IFN-j' clones administered i.v., a route which is not commonly used for immunotherapy in mice, was next evaluated. First, the immune memory against TSA-pc experimental metastasis elicited by MitC IFN-; clones injected i.v. was evaluated. The preimmunisation (day -30) with either MitC TSA-pc or IFN-, clones did not elicit protection against a TSA-pc i.v. challenge (day 0) (data not shown). By contrast, when MitC TSA-IFN-; clones were administered i.v. after an i.v. TSA-pc challenge, a significant inhibition in the number of lung nodules was found (Figure 4) . On the other hand, the same treatment with MitC TSA-pc actually enhanced the development of metastases. Taken together, these results suggest that the IFN--, released by transfectants in the lungs acts via inflammatory, rather than memory, components.
Therajlipy oftwllig colonies ii'itlh IFN-; pllis H-2"' double tr-ats/cctanits
The results with IFN-;, clones were encouraging, especially considering that TSA is a highly malignant tumour. Similar transfections yielded only clones expressing low levels of H-2 antigens, when cells which do not produce IFN-y were used as recipients (De Giovanni et al., 1994) . Other in vitro growth characteristics of double transfectants did not differ from those of parent TSA-IFNyl0 cells. In vivo, both the tumorigenicity and the metastatic ability of double transfectants in immunocompetent mice were almost completely abolished (Lollini et al., 1995) ; both T cells and macrophages were found to be involved in the rejection of these cells. In nude mice the tumorigenic potential of double transfectants was similar to that of control or parental cells, thus confirming the role played by T cells (Lollini et al., 1995) . Lymphocytes of mice immunised with cells transfected with IFN-y plus H-2 genes killed TSA-pc target cells even without in vitro restimulation (Figure 6 ), and their cytotoxic TSA is a highly malignant and poorly immunogenic mammary adenocarcinoma spontaneously arisen in a BALB/c mouse (Lollini et al., 1993) . TSA is quite refractory to conventional chemotherapy and immunotherapy, and reproduces many features of human mammary carcinomas (De Giovanni et al., 1988; Deabate et al., 1992) , thus it is a realistic model of human neoplasms. TSA cells have been used as recipients for many genes relevant to gene therapy of tumours, and it is one of the few systems available for comparative studies Allione et al., 1994) . In this paper we have shown that repeated injections of MitC IFN-y and allogeneic MHC class I gene-transduced TSA cells were effective in inhibiting lung metastases.
IFN-y receptors are ubiquitous, thus gene therapy with IFN genes will bring about phenotypic modifications of the target cell along with immunomodulation of the host. We have shown here that the autocrine effects can be rationally exploited to devise specific therapeutic modalities. both in the expression of some IFN-sensitive genes, including MHC (Watanabe et al., 1989; Gansbacher et al., 1990; Chen and Ananthaswamy, 1993; Mizuno et al., 1994) , and in the ability to colonise the lung after i.v. injection (Lollini et al., 1993 showed a higher therapeutic efficacy, with 30-80% of mice free from detectable metastatic nodules. This supports the idea that engineered tumour cells elicit a cross-talk between non-specific effectors and T lymphocytes, leading to a rapid destruction of tumour cells at the site of cytokine release and to the establishment of a systemic, long-term T-cell response that can reach and destroy distant metastatic deposits (Colombo et al., 1992) . Local tumour control can be effected by different inflammatory responses elicited by engineered tumour cells (Musiani et al., 1996) ; however, the expansion of an optimal Tcell reactivity is not always obtained (Colombo et al., 1992) . Our results show that both the route of vaccination and the use of additional antigenic stimuli can tip the balance in favour of a curative T-cell response.
The autocrine stimulation of genes containing IFN response elements in IFN-y-transduced cells suggested that these cells could also be used as efficient recipients of IFNsensitive genes. The allogeneic MHC genes, H-2K' and H2Db, were used to confer upon IFN-y transfectants an additional immunogenic signal. In the TSA model, IFN-y induced mainly a local macrophage response (Lollini et al., 1993; Musiani et al., 1994) ; allogeneic MHC gene products stimulate many T lymphocytes, and double IFN-y plus MHC gene transfectants were found to stimulate both macrophages and T lymphocytes simultaneously (Lollini et al., 1995 Present data acquire particular importance, since several phase I clinical trials using gene-transduced tumour cells are in progress, while the real efficacy of this approach is still controversial . About 50 different cell lines have been transduced worldwide with genes coding for IFN-y; however, the number of studies actually dealing with therapeutic protocols is still quite small. The therapeutic efficacy obtained in our model was similar to that attained in the Lewis lung carcinoma system (Porgador et al., 1993) ; other studies with MBT-2 bladder carcinoma (Connor et al., 1993) and Dunning rat prostate carcinoma (Vieweg et al., 1994 ) reported a limited therapeutic success with IFN-ysecreting cells. The studies present a number of common features: all used realistic models of malignant carcinomas; the therapeutic schedule comprised multiple administrations of similar doses of IFN-y-transduced cells; and therapeutic vaccinations started when neoplastic deposits (either local or metastatic) were quite small. As a whole, these results suggest that a gene therapy approach based on IFN-y is feasible and can be successful when the tumour load is small or metastatic deposits are still in the infancy of their natural history. Moreover, a rational exploitation of the biological properties of genetically engineered cells can further ameliorate the success rate obtained with the straightforward protocols adopted by earlier studies.
Finally, a crucial point of gene therapy with cytokine genes is which cytokine gives the best therapeutic results. No Il common pattern has emerged from comparative studies conducted using different experimental model systems (Dranoff et al., 1993; Hock et al., 1993; Allione et al., 1994; Franco et al., 1994) 
